Now, Moderna will deploy its mRNA technology to research vaccine approaches ... That starting point includes knowledge about viral structure, cell entry and the parts of the virus that might ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

SK bioscience won a patent case against Moderna in Korea, impacting mRNA technology development and potential vaccine exports ...

SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily ...